Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1876 to 1890 of 7682 results

  1. Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]

    In development [GID-TA10089] Expected publication date: 15 November 2017

    Technology appraisal guidance
    In development

  2. Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]

    Awaiting development [GID-TA10605] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]

    In development [GID-TA11036] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Oral semaglutide for managing overweight and obesity [ID6188]

    Awaiting development [GID-TA11149] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Ambulatory pulmonary artery pressure monitoring devices

    Awaiting development [GID-DG10087] Expected publication date: TBC

    Diagnostics guidance
    Awaiting development

  6. Concizumab for preventing bleeding episodes in haemophilia A or haemophilia B [ID5099]

    Awaiting development [GID-TA10972] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Leriglitazone for treating X-linked andrenoleukodystrophy TS ID 9996

    Awaiting development [GID-TA11393] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Letermovir for preventing cytomegalovirus infection in people under 18 years after allogeneic haematopoietic stem cell transplant TS ID 11868

    Awaiting development [GID-TA11361] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]

    Awaiting development [GID-TA11300] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Edaravone for treating amyotrophic lateral sclerosis TS ID 11869

    Awaiting development [GID-TA11362] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Epilepsies in children, young people and adults (extraordinary review)

    In development [GID-NG10378] Expected publication date: TBC

    NICE guideline
    In development

  12. Lenacapavir for treating multidrug resistant HIV-1 ID6196

    Suggested remit: To appraise the clinical and cost effectiveness of lenacapavir within its marketing authorisation for treating multidrug resistant HIV-1 for wh...

    Technology appraisal guidance
    Topic selection

  13. Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]

    In development [GID-TA11160] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over TS ID 11847

    Awaiting development [GID-TA11372] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]

    Awaiting development [GID-TA11214] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development